Hillary Norton, MD
Rheumatology · Santa Fe, NMNPI 1093911323
Payments from drug & device makers
Across 2,684 payments — averaging $1905.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2.5M
- AbbVie$731K
- Novartis$651K
- UCB, Inc.$294K
- Lilly USA, LLC$249K
- Eli Lilly$154K
- plus $485K from 30 others
Across 13 payments — averaging $4106.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$27K
- Sanofi US Services Inc.$17K
- Pfizer$5K
- Novartis Pharma AG$2K
- AbbVie$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 279 | $2,549,662 |
| AbbVie | 761 | $730,774 |
| Novartis | 231 | $651,201 |
| UCB, Inc. | 388 | $294,357 |
| Lilly USA, LLC | 407 | $249,195 |
| Eli Lilly | 51 | $153,513 |
| Johnson & Johnson | 116 | $95,360 |
| Sanofi US Services Inc. | 18 | $87,593 |
| Janssen Scientific Affairs, LLC | 70 | $77,694 |
| AstraZeneca | 120 | $66,167 |
| Pfizer | 72 | $59,508 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $32,354 |
| Sanofi | 23 | $15,479 |
| Bristol Myers Squibb | 27 | $9,843 |
| E.r. Squibb & Sons, L.L.C. | 19 | $9,698 |
| Gilead | 2 | $7,521 |
| Averitas Pharma Inc. | 4 | $5,378 |
| Regeneron | 12 | $5,229 |
| Regeneron Healthcare Solutions, Inc. | 10 | $3,819 |
| Sobi, Inc | 6 | $2,433 |
| Mallinckrodt Enterprises LLC | 4 | $2,066 |
| UCB SA | 2 | $1,710 |
| UCB Biosciences Inc. | 1 | $1,575 |
| Sanofi-aventis U.S. LLC | 15 | $376 |
| GSK | 11 | $222 |
| Mallinckrodt Hospital Products Inc. | 6 | $163 |
| PBG Puerto Rico LLC | 1 | $103 |
| Genentech USA, Inc. | 5 | $99 |
| Radius Health, Inc. | 5 | $91 |
| Boehringer Ingelheim | 2 | $61 |
| Arcutis Biotherapeutics, Inc. | 1 | $52 |
| Tersera Therapeutics LLC | 2 | $50 |
| Organon | 2 | $38 |
| Ferring Pharmaceuticals Inc. | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| Fresenius Kabi USA, LLC | 1 | $15 |
How this compares
$5,113,432 in reported general payments places this provider in the 95th percentile of 44 rheumatology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Santa Fe
- Susan BarrettSanta Fe$7K
- Rebecca FitzpatrickSanta Fe$1K
- Silver SisnerosSanta Fe$551
- Lyle AmerSanta Fe$55
- Leroy PachecoAlbuquerque$2.4M
- Arthur SnyderLas Cruces$1.5M
- Wilmer SibbittAlbuquerque$46K
- Ahmad RamahiRoswell$35K
- Adrian Michaella Mesilla$16K
- Albert RizzoliAlbuquerque$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.